Immuneering Corporation
IMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -7.30 | -0.05 | -15.99 |
| FCF Yield | -83.51% | -23.61% | -35.04% | -7.26% |
| EV / EBITDA | -0.53 | -2.65 | -1.17 | -10.57 |
| Quality | ||||
| ROIC | -139.63% | -61.46% | -44.02% | -20.81% |
| Gross Margin | 0.00% | 0.00% | 50.11% | 44.56% |
| Cash Conversion Ratio | 0.90 | 0.92 | 0.87 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -48.43% | 2.71% |
| Free Cash Flow Growth | -11.71% | -9.96% | -45.07% | -110.65% |
| Safety | ||||
| Net Debt / EBITDA | 0.50 | 0.95 | 1.32 | 2.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,001.98 | -1,008.66 | -7,267.50 | -398.20 |